The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study

Simple item page
dc.contributor.authorSadeghdoust, Mohammadamin
dc.contributor.authorAligolighasemabadi, Farnaz
dc.contributor.authorDehesh, Tania
dc.contributor.authorTaefehshokr, Nima
dc.contributor.authorSadeghdoust, Adel
dc.contributor.authorKotfis, Katarzyna
dc.contributor.authorHashemiattar, Amirhossein
dc.contributor.authorRavandi, Amir
dc.contributor.authorAligolighasemabadi, Neda
dc.contributor.authorVakili, Omid
dc.contributor.authorGrabarek, Beniamin
dc.contributor.authorStaszkiewicz, Rafał
dc.contributor.authorŁos, Marek J.
dc.contributor.authorMokarram, Pooneh
dc.contributor.authorGhavami, Saeid
dc.date.accessioned2023-03-01T23:04:27Z
dc.date.available2023-03-01T23:04:27Z
dc.date.issued2023-02-28
dc.date.updated2023-03-01T04:47:12Z
dc.description.abstractAbstract The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching. Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM. Graphical Abstracten_US
dc.identifier.citationArchivum Immunologiae et Therapiae Experimentalis. 2023 Feb 28;71(1):8
dc.identifier.citationArchivum Immunologiae et Therapiae Experimentalis. 2023 Feb 28;71(1):8
dc.identifier.urihttps://doi.org/10.1007/s00005-023-00672-1
dc.identifier.urihttp://hdl.handle.net/1993/37184
dc.language.isoengen_US
dc.language.rfc3066en
dc.publisherBMCen_US
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.subjectCOVID-19en_US
dc.subjectDiabetes mellitusen_US
dc.subjectStatinsen_US
dc.subjectPost-acute COVID-19 syndromeen_US
dc.subjectPulmonary fibrosisen_US
dc.titleThe Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Studyen_US
dc.typeresearch articleen_US
local.author.affiliationRady Faculty of Health Sciences::Max Rady College of Medicine::Department of Internal Medicineen_US
oaire.citation.issue1en_US
oaire.citation.startPage8en_US
oaire.citation.titleArchivum Immunologiae et Therapiae Experimentalisen_US
oaire.citation.volume71en_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
5_2023_Article_672.pdf
Size:
2.25 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship